Foghorn co-founder shows chromatin remodeling inhibition could treat sarcoma

Dana-Farber Cancer Institute researchers, including Foghorn Therapeutics Inc. (Cambridge, Mass.) co-founder Cigall Kadoch, and colleagues suggested inhibitors of the chromatin remodeling non-canonical BAF complex (ncBAF) could help treat sarcomas.

Three SWI/SNF complexes with distinct but overlapping protein subunits regulate chromatin remodeling and help establish stable, cell-specific gene expression patterns: canonical BAF (cBAF); polybromo-associated BAF (PBAF); and the recently identified ncBAF complex...